FR21C1057I1 - Composition pharmaceutique stable à dose fixe comprenant de la mométasone et de l'olopatadine - Google Patents
Composition pharmaceutique stable à dose fixe comprenant de la mométasone et de l'olopatadineInfo
- Publication number
- FR21C1057I1 FR21C1057I1 FR21C1057C FR21C1057C FR21C1057I1 FR 21C1057 I1 FR21C1057 I1 FR 21C1057I1 FR 21C1057 C FR21C1057 C FR 21C1057C FR 21C1057 C FR21C1057 C FR 21C1057C FR 21C1057 I1 FR21C1057 I1 FR 21C1057I1
- Authority
- FR
- France
- Prior art keywords
- olopatadine
- mometasone
- pharmaceutical composition
- stable fixed
- dose pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2975MU2013 | 2013-09-13 | ||
| PCT/IB2014/064251 WO2015036902A1 (fr) | 2013-09-13 | 2014-09-04 | Composition pharmaceutique stable à dose fixe comprenant de la mométasone et de l'azélastine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR21C1057I1 true FR21C1057I1 (fr) | 2022-01-21 |
| FR21C1057I2 FR21C1057I2 (fr) | 2023-02-03 |
Family
ID=51688369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR21C1057C Active FR21C1057I2 (fr) | 2013-09-13 | 2021-12-08 | Composition pharmaceutique stable à dose fixe comprenant de la mométasone et de l'olopatadine |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9078923B2 (fr) |
| EP (2) | EP3718533A1 (fr) |
| JP (2) | JP6203967B2 (fr) |
| BR (1) | BR112015018252B1 (fr) |
| CY (1) | CY1124675T1 (fr) |
| DK (1) | DK3043773T3 (fr) |
| ES (1) | ES2891729T3 (fr) |
| FR (1) | FR21C1057I2 (fr) |
| HR (1) | HRP20211515T1 (fr) |
| HU (1) | HUE056448T2 (fr) |
| LT (1) | LT3043773T (fr) |
| MX (1) | MX367674B (fr) |
| MY (1) | MY191380A (fr) |
| NL (1) | NL301154I2 (fr) |
| NO (1) | NO2021045I1 (fr) |
| PH (1) | PH12016500433A1 (fr) |
| PL (1) | PL3043773T3 (fr) |
| PT (1) | PT3043773T (fr) |
| RS (1) | RS62383B1 (fr) |
| SI (1) | SI3043773T1 (fr) |
| UA (1) | UA116793C2 (fr) |
| WO (1) | WO2015036902A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9937189B2 (en) | 2013-09-13 | 2018-04-10 | Glenmark Specialty S.A. | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
| US9370483B2 (en) * | 2013-09-13 | 2016-06-21 | Glenmark Specialty S.A. | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
| HUE056448T2 (hu) * | 2013-09-13 | 2022-02-28 | Glenmark Specialty Sa | Stabil, rögzített adagolású gyógyszerkészítmény, amely mometazont és olopatadint tartalmaz orrba történõ beadásra |
| JP6419195B2 (ja) | 2013-10-04 | 2018-11-07 | グレンマーク・スペシャルティー・エスエー | モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療 |
| US10548907B2 (en) | 2013-10-04 | 2020-02-04 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
| US10758550B2 (en) | 2013-10-04 | 2020-09-01 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
| US10653661B2 (en) | 2013-10-04 | 2020-05-19 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
| US10016443B2 (en) | 2013-10-04 | 2018-07-10 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
| US11679210B2 (en) | 2014-10-03 | 2023-06-20 | Glenmark Specialty S.A. | Dispensing device and pharmaceutical composition for the treatment of rhinitis |
| WO2016155021A1 (fr) | 2015-04-03 | 2016-10-06 | 绿仕科技控股有限公司 | Système de surveillance de l'environnement |
| BR112018076537A2 (pt) * | 2017-06-28 | 2019-04-02 | Glenmark Specialty S.A. | dispositivo de distribuição e composição farmacêutica para administração nasal a um humano |
| TWI790316B (zh) * | 2017-12-14 | 2023-01-21 | 瑞士商葛蘭馬克專業股份公司 | 用於向人類經鼻投與之含有水性醫藥組合物的分配裝置 |
| WO2020070599A1 (fr) * | 2018-10-05 | 2020-04-09 | Glenmark Specialty S.A. | Composition de nébulisation de mométasone |
| CN109602693A (zh) * | 2018-11-13 | 2019-04-12 | 华润三九（南昌）药业有限公司 | 糠酸莫米松凝胶及其制备方法 |
| US20230000814A1 (en) * | 2019-12-06 | 2023-01-05 | Toko Yakuhin Kogyo Co., Ltd. | Pharmaceutical composition comprising steroid compound and olopatadine |
| AU2021291684A1 (en) * | 2020-06-15 | 2022-12-08 | Alkem Laboratories Limited | Combination of alcaftadine and a corticosteroid |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4923892A (en) | 1985-08-17 | 1990-05-08 | Burroughs Wellcome Co. | Tricyclic aromatic compounds |
| GB8520662D0 (en) | 1985-08-17 | 1985-09-25 | Wellcome Found | Tricyclic aromatic compounds |
| US6127353A (en) | 1991-09-06 | 2000-10-03 | Schering Corporation | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
| US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| WO2001026658A2 (fr) | 1999-10-08 | 2001-04-19 | Schering Corporation | Traitement nasal topique |
| US7977376B2 (en) | 2001-06-27 | 2011-07-12 | Novartis Ag | Olopatadine formulations for topical nasal administration |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| JP2006508138A (ja) * | 2002-11-12 | 2006-03-09 | アルコン，インコーポレイテッド | アレルギー性鼻炎を処置するための抗アレルギー剤およびステロイドの使用 |
| US8912174B2 (en) * | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
| PL1814538T3 (pl) | 2004-11-24 | 2010-02-26 | Alcon Inc | Sposób dostarczania donosowego sprayu |
| US20070099883A1 (en) * | 2005-10-07 | 2007-05-03 | Cheryl Lynn Calis | Anhydrous mometasone furoate formulation |
| CA2631757A1 (fr) * | 2005-12-02 | 2007-06-07 | Elan Pharma International Limited | Nouvelles compositions de mometasone et procedes de fabrication et utilisation de celles-ci |
| EP1981475A2 (fr) * | 2006-02-09 | 2008-10-22 | Schering Corporation | Formulations pharmaceutiques |
| GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
| WO2008047149A1 (fr) | 2006-10-19 | 2008-04-24 | Cipla Limited | Compositions pharmaceutiques et pulvérisation nasale incorporant du furoate de mométasone anhydre |
| CN106038481A (zh) * | 2007-06-28 | 2016-10-26 | 锡德克斯药物公司 | 皮质类固醇水溶液的鼻部和眼部给药 |
| US8642069B2 (en) | 2008-08-27 | 2014-02-04 | Alexander D. Goldin | Composition and method for treating colds |
| JP2012505236A (ja) * | 2008-10-10 | 2012-03-01 | シェーリング コーポレイション | コルチコステロイド組成物およびそれの治療方法 |
| WO2011141929A2 (fr) | 2010-05-11 | 2011-11-17 | Cadila Healthcare Limited | Compositions pharmaceutiques aqueuses de fluticasone et d'olopatadine |
| KR101261230B1 (ko) * | 2010-11-29 | 2013-05-07 | 한림제약(주) | 모메타손 푸로에이트 및 아젤라스틴 염산염을 포함하는 비내 투여용 약학 조성물 |
| BR112013017183A2 (pt) | 2011-01-04 | 2017-07-25 | Bausch & Lomb | composições de bepostatina |
| FR2970180B1 (fr) | 2011-01-06 | 2013-08-02 | Substipharm Dev | Procede de preparation de suspensions aqueuses pharmaceutiques comprenant un medicament efficace dans le traitement des rhinites |
| KR20140081925A (ko) | 2012-12-12 | 2014-07-02 | 한미약품 주식회사 | 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제 |
| HUE056448T2 (hu) * | 2013-09-13 | 2022-02-28 | Glenmark Specialty Sa | Stabil, rögzített adagolású gyógyszerkészítmény, amely mometazont és olopatadint tartalmaz orrba történõ beadásra |
-
2014
- 2014-09-04 HU HUE14781946A patent/HUE056448T2/hu unknown
- 2014-09-04 LT LTEPPCT/IB2014/064251T patent/LT3043773T/lt unknown
- 2014-09-04 PL PL14781946T patent/PL3043773T3/pl unknown
- 2014-09-04 HR HRP20211515TT patent/HRP20211515T1/hr unknown
- 2014-09-04 PT PT147819460T patent/PT3043773T/pt unknown
- 2014-09-04 BR BR112015018252-6A patent/BR112015018252B1/pt active IP Right Grant
- 2014-09-04 ES ES14781946T patent/ES2891729T3/es active Active
- 2014-09-04 DK DK14781946.0T patent/DK3043773T3/da active
- 2014-09-04 SI SI201431884T patent/SI3043773T1/sl unknown
- 2014-09-04 UA UAA201507123A patent/UA116793C2/uk unknown
- 2014-09-04 EP EP20163589.3A patent/EP3718533A1/fr active Pending
- 2014-09-04 MY MYPI2015702415A patent/MY191380A/en unknown
- 2014-09-04 JP JP2016542408A patent/JP6203967B2/ja active Active
- 2014-09-04 RS RS20211201A patent/RS62383B1/sr unknown
- 2014-09-04 EP EP14781946.0A patent/EP3043773B1/fr active Active
- 2014-09-04 MX MX2015013965A patent/MX367674B/es active IP Right Grant
- 2014-09-04 WO PCT/IB2014/064251 patent/WO2015036902A1/fr active Application Filing
- 2014-09-11 US US14/483,837 patent/US9078923B2/en active Active
-
2016
- 2016-03-07 PH PH12016500433A patent/PH12016500433A1/en unknown
-
2017
- 2017-08-30 JP JP2017165305A patent/JP6664358B2/ja active Active
-
2021
- 2021-09-28 CY CY20211100852T patent/CY1124675T1/el unknown
- 2021-10-22 NO NO2021045C patent/NO2021045I1/no unknown
- 2021-12-08 FR FR21C1057C patent/FR21C1057I2/fr active Active
- 2021-12-16 NL NL301154C patent/NL301154I2/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015013965A (es) | 2016-02-10 |
| CY1124675T1 (el) | 2022-07-22 |
| PT3043773T (pt) | 2021-10-04 |
| PL3043773T3 (pl) | 2021-12-13 |
| JP2017206560A (ja) | 2017-11-24 |
| RU2015128497A (ru) | 2017-10-18 |
| SI3043773T1 (sl) | 2021-12-31 |
| MY191380A (en) | 2022-06-21 |
| EP3718533A1 (fr) | 2020-10-07 |
| HUE056448T2 (hu) | 2022-02-28 |
| DK3043773T3 (da) | 2021-10-04 |
| MX367674B (es) | 2019-08-30 |
| NO2021045I1 (no) | 2021-10-22 |
| US9078923B2 (en) | 2015-07-14 |
| EP3043773B1 (fr) | 2021-06-30 |
| RS62383B1 (sr) | 2021-10-29 |
| EP3043773A1 (fr) | 2016-07-20 |
| US20150079178A1 (en) | 2015-03-19 |
| RU2015128497A3 (fr) | 2018-05-11 |
| JP6664358B2 (ja) | 2020-03-13 |
| WO2015036902A1 (fr) | 2015-03-19 |
| ES2891729T3 (es) | 2022-01-31 |
| NL301154I2 (nl) | 2022-07-18 |
| LT3043773T (lt) | 2021-10-11 |
| BR112015018252B1 (pt) | 2023-01-10 |
| BR112015018252A2 (pt) | 2017-07-18 |
| RU2687551C2 (ru) | 2019-05-15 |
| FR21C1057I2 (fr) | 2023-02-03 |
| HRP20211515T1 (hr) | 2021-12-24 |
| JP2016534142A (ja) | 2016-11-04 |
| PH12016500433A1 (en) | 2016-05-16 |
| UA116793C2 (uk) | 2018-05-10 |
| JP6203967B2 (ja) | 2017-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR21C1057I2 (fr) | Composition pharmaceutique stable à dose fixe comprenant de la mométasone et de l'olopatadine | |
| CY2018022I1 (el) | Πολυκυκλικες ενωσεις καρβαμοϋλπυριδονης και φαρμακευτικη χρηση αυτων | |
| MA46820A (fr) | Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques | |
| MA42950A (fr) | Administration d'agents de potentialisation de cftr modifiés au deutérium | |
| MA52257A (fr) | Compositions pharmaceutiques comprenant blautia et leur administration orale | |
| BR112016003229A2 (pt) | Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| BR112013023174A2 (pt) | "compostos derivados de triterpenoide de c4-monometila, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos" | |
| DK3479819T3 (da) | Stabilt væskeformigt farmaceutisk præparat | |
| ES2968132T3 (es) | Preparación farmacéutica de palbociclib y uso médico de la misma | |
| KR20220012274A9 (ko) | 플루오린 함유 화합물 및 이의 항암 의학적 용도 | |
| FR2958157B1 (fr) | Composition cosmetique et pharmaceutique comprenant du n-acetyl-glucosamine-6-phosphate | |
| DK3709978T3 (da) | Farmaceutisk oral formulering omfattende bakterier | |
| HK1215388A1 (zh) | 可吸入藥用組合物和含有該藥用組合物的吸入器裝置 | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| DK3554534T3 (da) | Farmaceutisk sammensætning omfattende insulin | |
| DK3275452T3 (da) | Farmaceutisk sammensætning med silibinin | |
| BR112017013012A2 (pt) | compostos de indenil, composições farmacêuticas e usos médicos destes | |
| MA40781A (fr) | Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale | |
| BR112014025416A2 (pt) | AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS. | |
| MA52644A (fr) | Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation | |
| MA49822A (fr) | Combinaison pharmaceutique comprenant du ponesimod | |
| HK1215167A1 (zh) | 可吸入藥用組合物和含有該藥用組合物的吸入器裝置 | |
| MA45158A (fr) | Composition pharmaceutique comprenant de l'éteplirsen | |
| DK3275457T3 (da) | Farmaceutisk sammensætning omfattende silybin og pu'er-te-essens | |
| MA43114A (fr) | Formulation combinée à dose fixe d'éflornithine et sulindac |